Milestone Pharmaceuticals Inc. (NASDAQ:MIST) Short Interest Update

Milestone Pharmaceuticals Inc. (NASDAQ:MIST) was the recipient of a significant growth in short interest during the month of February. As of February 28th, there was short interest totalling 742,800 shares, a growth of 86.3% from the February 13th total of 398,700 shares. Approximately 1.5% of the shares of the company are short sold. Based on an average daily trading volume, of 817,700 shares, the days-to-cover ratio is presently 0.9 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $25.00 price objective on shares of Milestone Pharmaceuticals in a report on Friday, February 28th.

Milestone Pharmaceuticals Stock Performance

Shares of MIST traded up $0.14 during trading hours on Friday, reaching $2.17. 2,438,222 shares of the company traded hands, compared to its average volume of 388,516. The stock has a market capitalization of $115.72 million, a P/E ratio of -2.68 and a beta of 1.83. The company has a quick ratio of 15.40, a current ratio of 15.40 and a debt-to-equity ratio of 2.18. Milestone Pharmaceuticals has a 12-month low of $1.12 and a 12-month high of $2.75. The business has a fifty day moving average price of $2.02 and a 200-day moving average price of $1.80.

Institutional Investors Weigh In On Milestone Pharmaceuticals

Hedge funds have recently added to or reduced their stakes in the business. Jones Financial Companies Lllp boosted its holdings in Milestone Pharmaceuticals by 1,000.0% in the fourth quarter. Jones Financial Companies Lllp now owns 11,000 shares of the company’s stock valued at $26,000 after purchasing an additional 10,000 shares during the last quarter. National Bank of Canada FI boosted its holdings in Milestone Pharmaceuticals by 163.4% in the fourth quarter. National Bank of Canada FI now owns 18,700 shares of the company’s stock valued at $44,000 after purchasing an additional 11,600 shares during the last quarter. PVG Asset Management Corp purchased a new stake in Milestone Pharmaceuticals in the third quarter valued at $46,000. Atria Investments Inc boosted its holdings in Milestone Pharmaceuticals by 44.4% in the third quarter. Atria Investments Inc now owns 40,421 shares of the company’s stock valued at $61,000 after purchasing an additional 12,430 shares during the last quarter. Finally, Cubist Systematic Strategies LLC purchased a new stake in Milestone Pharmaceuticals in the fourth quarter valued at $73,000. 86.18% of the stock is owned by hedge funds and other institutional investors.

Milestone Pharmaceuticals Company Profile

Milestone Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate.